Will allogeneic CAR T cells for CD19 malignancies take autologous CAR T cells 'off the shelf'?
Amanda M DiNofia, Stephan A Grupp
Author Information
- Amanda M DiNofia: Cancer Immunotherapy Program, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Stephan A Grupp: Cancer Immunotherapy Program, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA, USA. grupp@chop.edu. ORCID
No abstract text available.
- Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
[DOI: 10.1056/NEJMoa1709866]
- Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
[DOI: 10.1056/NEJMoa1707447]
- Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414–5424 (2020).
[DOI: 10.1182/bloodadvances.2020003092]
- Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020).
[DOI: 10.1038/s41573-019-0051-2]
- Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885–1894 (2020).
[DOI: 10.1016/S0140-6736(20)32334-5]
- Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl Med. 9, eaaj2013 (2017).
[DOI: 10.1126/scitranslmed.aaj2013]
- Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 T cells. J. Clin. Invest. 115, 1616–1626 (2005).
[DOI: 10.1172/JCI24480]
- Tumeh, P. C. et al. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J. Immunother. 33, 759–768 (2010).
[DOI: 10.1097/CJI.0b013e3181f1d644]
- Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100–1109 (2018).
[DOI: 10.1158/2326-6066.CIR-17-0405]
- Neelapu, S. S. et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. J. Clin. Oncol. 38 (Suppl. 15), 8002 (2020).
[DOI: 10.1200/JCO.2020.38.15_suppl.8002]
Adult
Antigens, CD19
B-Lymphocytes
Child
Hematopoietic Stem Cell Transplantation
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
T-Lymphocytes
Antigens, CD19
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
